Medical treatment of colonic diverticular disease: are we sure the aim is right?

Bassotti, Gabrio; Villanacci, Vincenzo

doi:10.1007/s11739-011-0562-2

Cited by 2 publications

(2 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Major markers of atherosclerosis (HS and CPs) that assess the global damage due to metabolic and inflammatory determinants [14] are affected in PsA subjects [9,13,16]. Accordingly, subjects who exhibit a high prevalence of HS and of CPs are likely to have experienced a more severe inflammatory state [12-15].…”

Section: Discussionmentioning

confidence: 99%

Hepatic steatosis, carotid plaques and achieving MDA in psoriatic arthritis patients starting TNF-α blockers treatment: a prospective study

Minno

Peluso

Iervolino³

et al. 2012

Arthritis Res Ther

View full text Add to dashboard Cite

IntroductionWe prospectively evaluated whether hepatic steatosis (HS) and the presence of carotid plaques (CPs) impacts on achieving minimal disease activity (MDA) in psoriatic arthritis (PsA) patients starting tumor necrosis factor (TNF)-α blockers treatment.MethodsBefore starting treatment with TNF-α blockers, consecutive PsA subjects with an active disease were evaluated for the presence of the metabolic syndrome (MetS), HS and CPs. The incidence of MDA was evaluated 12 and 24 months later.ResultsAmong 270 PsA subjects, 91 (33.7%) exhibited the MetS, 58 (21.5%) CPs and 76 (28.1%) HS. At the 12-month follow-up, 98 (36.3%) individuals achieved MDA. Compared with those who did, a higher prevalence of the MetS, HS and CPs was found in subjects who did not achieve the MDA (P always < 0.001). After adjusting for the MetS and for all the other demographic/clinical characteristics analyzed, the presence of HS and CPs at baseline independently predicted the risk of not achieving MDA (Hazard Ratio: 1.91, 95% confidence interval (CI): 1.04 to 3.38, P = 0.035 and Hazard Ratio: 3.21, 95%CI: 1.64 to 6.29, P = 0.001, respectively). Separate Kaplan-Meier survival models confirmed this (Log-Rank: 12.894, P < 0.001 and Log-Rank: 12.849, P < 0.001, respectively). Compared with those without, progressively increasing Hazard Ratios of not achieving MDA were found in those with HS, CPs or HS + CPs at baseline. Moreover, the presence of HS and/or CPs predicted the risk of relapse during the additional 12-month follow-up (Hazard Ratio: 2.85, 95%CI: 1.27 to 6.37, P = 0.011 and Hazard Ratio: 3.17, 95%CI: 1.57 to 6.41, P = 0.001 respectively).ConclusionsHS and/or CPs at baseline are negative predictors of achieving and maintaining MDA.

show abstract

Section: Discussionmentioning

confidence: 99%

Hepatic steatosis, carotid plaques and achieving MDA in psoriatic arthritis patients starting TNF-α blockers treatment: a prospective study

Minno

Peluso

Iervolino³

et al. 2012

Arthritis Res Ther

View full text Add to dashboard Cite

show abstract

“…An increased CV risk has been documented also in subjects with spondyloarthritides [112, 113] and other systemic inflammatory diseases, such as rheumatoid arthritis, Sjogren syndrome, and systemic lupus erythematosus [114, 115]. Both in psoriatic arthritis and in AS, an impaired vascular flow-mediated dilation and carotid intima-media thickening [116–118] have been found.…”

Section: Cardiovascular Disease and Eamentioning

confidence: 99%

Enteropathic Spondyloarthritis: From Diagnosis to Treatment

Peluso

Minno

Iervolino

et al. 2013

Clinical and Developmental Immunology

View full text Add to dashboard Cite

Enteropathic arthritis (EA) is a spondyloarthritis (SpA) which occurs in patients with inflammatory bowel diseases (IBDs) and other gastrointestinal diseases. Diagnosis is generally established on the medical history and physical examination. It was, generally, made according to the European Spondyloarthropathy Study Group (ESSG) criteria. Rheumatic manifestations are the most frequent extraintestinal findings of IBD with a prevalence between 17% and 39%, and IBD is associated, less frequently, with other rheumatic disease such as rheumatoid arthritis, Sjogren syndrome, Takayasu arteritis, and fibromyalgia. Although the pathogenesis of EA has not been plainly clarified, the most popular theory supposes that joint inflammation occurs in genetically predisposed subjects with bacterial gut infections, provided an important evidence for a possible relationship between inflammation of the gut mucosa and arthritis. The management of patients with EA requires an active cooperation between the gastroenterologist and rheumatologist.

show abstract

Medical treatment of colonic diverticular disease: are we sure the aim is right?

Cited by 2 publications

References 17 publications

Hepatic steatosis, carotid plaques and achieving MDA in psoriatic arthritis patients starting TNF-α blockers treatment: a prospective study

Hepatic steatosis, carotid plaques and achieving MDA in psoriatic arthritis patients starting TNF-α blockers treatment: a prospective study

Enteropathic Spondyloarthritis: From Diagnosis to Treatment

Contact Info

Product

Resources

About